Slovenija - slovenščina - Ecolab

ecolab deutschland gmbh -

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

boehringer ingelheim vetmedica gmbh 55216 ingelheim/rhein nemČija 2 -

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

boehringer ingelheim vetmedica gmbh 55216 ingelheim/rhein nemčija 2 -

Evropska unija - slovenščina - EMA (European Medicines Agency)

lantheus eu limited - perflutren - ehokardiografija - kontrastni mediji - to zdravilo je samo za diagnostično uporabo. luminity je ultrazvok kontrast-krepitev sredstvo za uporabo pri bolnikih, pri katerih ne-kontrast echocardiography bil neoptimalne (neoptimalne, se šteje, da kažejo, da je vsaj dve od šestih segmentov v 4 - ali 2-zbornica pogled na prekata meje niso bile ovrednoten), in ki so sum, ali sedež koronarne bolezni, zagotoviti opacification srčne komore in izboljšanje levega prekata endocardial mejne razmejitve, na obeh počitek in stres.

Evropska unija - slovenščina - EMA (European Medicines Agency)

cipla (eu) limited - olanzapin - schizophrenia; bipolar disorder - psiholeptiki - adultsolanzapine je primerna za zdravljenje shizofrenije. olanzapin je učinkovita pri ohranjanju klinično izboljšanje, med nadaljevanje terapije pri bolnikih, ki so pokazali začetni odziv zdravljenje. olanzapin je primerna za zdravljenje zmerno do hudo manične epizode. pri bolnikih, katerih manične epizode se je odzvala na olanzapin zdravljenje, olanzapin, je indicirano za preprečevanje ponovitve pri bolnikih z bipolarno motnjo.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

(eu) norbrook laboratories (ireland) ltd -

Evropska unija - slovenščina - EMA (European Medicines Agency)

tmc pharma (eu) limited - fosdenopterin hydrobromide dihydrate - metal metabolism, inborn errors - drugi zdravljene bolezni prebavil in presnove izdelki, - nulibry is indicated for the treatment of patients with molybdenum cofactor deficiency (mocd) type a.

Evropska unija - slovenščina - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastična sredstva - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfom, mantle cell - antineoplastična sredstva - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Evropska unija - slovenščina - EMA (European Medicines Agency)

fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - vsi drugi terapevtski izdelki - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.